Ukraine may face drugs shortage this year

11 August 2014

Ukraine plans to ban pharmaceutical imports from Russia, except 20 vital drugs, the analogues of which are not produced in Ukraine, according to Oleg Musy, Ukraine’s Health Minister.

He added that the government and the national Anti-Monopoly Service plans to accelerate the fight with those pharmaceutical companies which have significantly increased prices for their drugs since the beginning of the military conflict in Ukraine in April of the current year.

According to Mr Musy, as part of this, there are plans for the abolishment of the results of tenders, where wholesale prices set by producers were significantly higher than the average European Union levels.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >